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Background: The aim of this study was to determine the oxidant–antioxidant status and 
lipid peroxidation products, as well as paraoxonase and atherosclerotic plaque formation, in a 
hypercholesterolemic atherosclerosis rabbit model to investigate the effects of atorvastatin in 
the atherosclerotic process.
Methods: Forty male New Zealand rabbits were divided into four groups, ie, a control group 
receiving standard pellets, a group receiving atorvastatin therapy, a hypercholesterolemic group 
receiving an atherogenic diet, and a group receiving both an atherogenic diet and atorvastatin.
Results: The atherogenic diet increased the levels of low-density lipoprotein (LDL) thiobarbi-
turic acid reactive substances (1.84 vs 3.79 nmol/mg protein) and LDL-conjugated diene (147 
vs 318 µmol/mg protein) after induction of oxidation by Cu2+, despite an increase of superoxide 
dismutase activity. Treatment with atorvastatin limited LDL oxidation significantly (LDL thio-
barbituric acid reactive substances 2.19 nmol/mg protein, LDL-conjugated diene 222 µmol/mg 
protein). Paraoxonase, which prevents LDL oxidation and inactivates LDL-derived oxidized 
phospholipids, showed a pronounced decrease in the group receiving the atherogenic diet 
(110 U/L to 28 U/L), and atorvastatin treatment increased paraoxonase activity.   Histological 
examination of arcus aorta tissues from the hypercholesterolemic group showed abundant 
plaque formation surrounding and obstructing the lumen, whereas treatment with atorvastatin 
prevented or limited plaque formation, keeping the plaque thin and localized.
Conclusion: Atorvastatin has dramatic antiatherosclerotic effects, part of which seems to be 
due to the antioxidant features of the parent drug and/or its metabolites, favoring inhibition of 
LDL oxidation.
Keywords: atherosclerosis, atorvastatin, hypercholesterolemia, low-density lipoprotein 
  oxidation, paraoxonase
Introduction
Atherogenesis is a chronic inflammatory process that involves a complex interplay 
between circulating cellular and blood elements and the cells of the arterial wall.1,2 
While many factors are involved, the “oxidation hypothesis” has been a central focus 
in the investigation of the pathogenesis of the atherosclerotic process, suggesting that 
the oxidative modification of low-density lipoprotein (LDL), or other lipoproteins, is 
central, if not obligatory for the atherogenic process.3,4
Oxidation of LDL is a lipid peroxidation process resulting in formation of a wide 
range of biologically active products, including peroxides and malondialdehyde. 
  Oxidation of LDL results in the generation of aldehydes that substitute lysine residues 
in the apoprotein B-100 moiety of LDL and causes apolipoprotein B-100 fragmentation. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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As a result, the particle loses its affinity for the LDL receptor 
and binds avidly to scavenger receptors on macrophages, 
resulting in foam cell formation.5,6
Advances in the management of hypercholesterolemia 
are primarily due to the development of the 3-hydroxy-3-
methylglutaryl coenzyme (HMG-Co A) reductase inhibitors, 
ie, the statins.7 Recently, many statins have been used for 
their overall antihypercholesterolemic action in patients with 
atherosclerosis. They are presumed to work by upregulat-
ing the LDL receptor, thereby lowering LDL cholesterol in 
particular. In addition to lowering cholesterol levels, statins 
seem to act on the formation and progression of athero-
sclerotic plaque through alternative mechanisms involved 
in progression of the disease.8 The various statins differ in 
their pharmacokinetics, therapeutic efficacy, drug interac-
tions, dosage, and administration, and therefore they differ 
in their potential advantages and disadvantages. Reduction 
of lipid peroxidation may be one of the important features 
explaining the favorable effect of statins in preventing or 
reducing atherosclerosis. Even though some investigators 
have shown the antioxidant potential of statins in vitro,8 in 
vitro investigations may not be the best approach to evalu-
ate the effects of these agents because many other relevant 
events may be taking place in vivo.
In this study, we examined lipid peroxidation products, 
ie, thiobarbituric acid reactive substances (TBARS) and 
LDL-conjugated diene, formed as a result of oxidative stress 
generated in a hypercholesterolemic atherosclerosis model 
in rabbits. The antioxidant activity of defensive enzymes, 
including superoxide dismutase, catalase, and paraoxonase, 
was also investigated to determine oxidative status. The 
effects of atorvastatin, a potent HMG-Co A reductase inhibi-
tor, with the longest half-life of its group, was evaluated for 
its influence on lipid profiles, lipid peroxidation, and the anti-
oxidant system, as well as its impact on paraoxonase activity. 
In addition, atherosclerotic plaque formation and the outcome 
of atorvastatin treatment was assessed histopathologically.
Methods
Animal model
Forty male New Zealand rabbits weighing 2.5–3.5 kg were 
used for the hypercholesterolemic animal model. The study 
protocol was reviewed and approved by the ethics committee 
of the Ege University Medical School. All the animals were 
housed in individual cages and were quarantined for 7 days 
prior to the study, and received standard pellets (15% protein, 
2.5% lipid, 15% cellulose, 14% clay, 13% water) during this 
time. The rabbits were then divided into four groups: Group 1, 
which received standard pellets of 100 g/kg/day for 15 weeks 
(controls, n = 11); Group 2, which received standard pellets 
for 15 weeks, with atorvastatin 5 mg/kg/day added from 
week 7 and continued until the end of week 15 (atorvastatin 
group, n = 10); Group 3, which received an atherogenic diet 
(100 g/kg/day, 2% cholesterol, 1.5% butter added to standard 
pellets) for 15 weeks (atherogenic diet group, n = 9); and 
Group 4, which received an atherogenic diet with atorvastatin 
added from week 7 until the end of week 15 (atherogenic 
diet + atorvastatin group, n = 10). Blood samples were col-
lected from the ear veins of all rabbits at baseline, at week 7 
just before starting atorvastatin treatment, and at the end of 
the study at week 15. All blood samples were obtained after 
an overnight fast, and all serum and plasma was immediately 
separated. All animals were sacrificed using an overdose of 
pentobarbital. The study and its design were approved by 
the local ethics and research committee of Ege University, 
Faculty of Medicine.
Serum analysis
Serum samples were stored at -80°C until analysis. Serum 
paraoxonase activity was measured using the synthetic 
substrate, paraoxon (diethyl-ρ-nitrophenyl phosphate). 
  Paraoxonase activity towards paraoxon was assessed by 
measuring liberation of ρ-nitrophenol. The ρ-nitrophenol 
production rate at 405 nm was recorded for 2.5 minutes at 
15-second intervals. Other serum parameters, ie, total choles-
terol, triglyceride, high-density lipoprotein (HDL) cholesterol 
and LDL cholesterol, were determined by routine commercial 
kits (Randox Laboratories Ltd, County Antrim, Ireland).
erythrocyte analysis
After separation of plasma, the packed erythrocytes were 
washed twice with 9 g/L NaCl solution and hemolyzed with ice-
cold water (1/5, v/v). Superoxide dismutase activity and cata-
lase activity were determined immediately in the hemolysates. 
Hemoglobin values were measured by Drabkin’s method.9
Superoxide dismutase activity was measured spectro-
photometrically based on the inhibition of epinephrine auto-
oxidation by superoxide dismutase at 480 nm as described 
by Sozmen et al, using a Shimadzu UV-120 spectropho-
tometer (Kyoto, Japan). The assay was calibrated using 
purified superoxide dismutase, and 1 unit of enzyme was 
defined as the amount that inhibits 50% of auto-oxidation 
of epinephrine.10
Catalase activity was determined as described by 
Aebi.11 The degradation of hydrogen peroxide (H2O2) by 
the catalase enzyme was recorded spectrophotometrically Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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at 240 nm. One unit of catalase was defined as the amount 
of enzyme that decomposes 1 µmol H2O2/minute under 
specific conditions.
For measurement of TBARS levels, thiobarbituric acid 
0.12 M in trichloroacetic acid 15% and HCl 1% was added 
to the hemolysates and boiled at 100°C for 20 minutes. After 
centrifugation at 2000 rpm for 10 minutes, absorbance of the 
supernatant at 532 nm was measured spectrophotometrically. 
The results were calculated as nmol/mL with respect to stan-
dards prepared with 1,1,3,3-tetraetoxypropane. The results 
are given as nmol/g of hemoglobin.
LDL isolation and in vitro oxidation
Plasma samples were incubated at room temperature for 
30 minutes with a commercial precipitant reagent (Merck, 
Darmstadt, Germany), as suggested by Taus et al.12 After 
centrifugation at 1600 g for 10 minutes, LDL samples were 
solubilized using sodium hydroxide 0.15 M. LDL oxidation 
was assessed by TBARS and LDL-conjugated diene levels in 
LDL samples containing 200 µg of protein. LDL oxidation 
was monitored at 234 nm with a Shimadzu UV-120 spectro-
photometer, and the calculations were performed using an 
extinction coefficient of 29,500 L/mol/cm.
In vitro oxidation of LDL was induced by incubating the 
isolated lipoproteins with copper sulfate (CuSO4) 5 µM, and 
LDL-conjugated diene formation was analyzed by monitoring 
the absorbance change at 234 nm over 3 hours at 5-minute 
intervals. The peak of diene conjugation was observed and 
assessed at minute 110 after stimulation of in vitro oxidation 
of LDL (sLDL diene) with CuSO4. TBARS levels (sLDL 
TBARS) were also determined at this point. Protein measure-
ments were performed according to Lowry’s method.13
Tissue analysis
Arcus aortic tissues were removed and washed in saline. For 
the biochemical assays, aortic tissues were homogenized 
in ice-cold phosphate buffer and centrifuged at 2000 g for 
10 minutes. Superoxide dismutase and catalase assays were 
done, as described for the hemolysate measurements.
Malondialdehyde levels were measured using a com-
mercial kit (LPO-586; Oxis Research, Beverly Hills, CA). 
The assay is based on a chromogenic reaction, ie, N-methyl-
2-phenylindole with malondialdehyde. The results were 
calculated as nmol/g protein with respect to the calibration 
curve prepared with 1,1,3,3-tetraethoxypropane.
The arcus aortic tissues were fixed with formaldehyde 
10% for histopathological examination. After fixation, the 
arteries were embedded in paraffin and cross-sectioned into 
slices of 4–5 µm thickness at 5 mm intervals. The cross-
sections of aortic tissue were stained with hematoxylin and 
eosin, and examined using an Olympus BH-2 light micro-
scope (Tokyo, Japan).
Statistical analysis
Statistical analyses were performed using the statistical SPSS 
package program for Windows, (v 11; SPSS Inc,   Chicago, IL). 
Comparisons of parameters between the different groups 
were done using the nonparametric Mann–Whitney U test. 
Statistical evaluations within the groups were done using 
the Wilcoxon signed-rank test. P , 0.05 was considered to 
indicate a statistically significant difference for both tests.
Results
Lipid profile
As expected, the atherogenic diet caused a pronounced 
increase in all lipid fractions (P , 0.01, Table 1). Atorvastatin 
treatment achieved a significant 32.7% decrease (P , 0.01) in 
total cholesterol, a 25.5% decrease (P , 0.01) in LDL cho-
lesterol, and a 14% decrease in HDL cholesterol (P , 0.01) 
in Group 4. In our model, treatment with atorvastatin did not 
cause a significant change in triglyceride levels.
Oxidative status of erythrocytes
Analysis at week 7 showed that the atherogenic diet caused a 
significant increase (P , 0.01) in superoxide dismutase and 
catalase activity in Group 3 and Group 4 compared with basal 
levels (Table 2). The atherogenic diet for 7 weeks doubled 
the TBARS levels (P , 0.01) in Group 3 and Group 4. While 
treatment with atorvastatin led to a significant decrease in 
superoxide dismutase activity (P , 0.05) and TBARS levels 
(P , 0.05), it had no significant effect on catalase activity 
in Group 4. Comparison of superoxide dismutase levels in 
the second and final blood samples indicated that the super-
oxide dismutase levels in Group 3 (atherogenic diet without 
treatment) continued to increase in the second half of the 
experiment but the increase was not statistically significant. 
Even though catalase activity was modified by atorvastatin 
treatment, the change was not statistically significant, in 
contrast with superoxide dismutase activity (Table 2).
LDL oxidation and paraoxonase
TBARS and LDL-conjugated diene levels are shown in 
Figure 1. Basal levels were measured at 0 minutes (bLDL 
TBARS and bLDL diene) before induction of Cu2+ oxidation, 
and stimulated levels were measured at minute 110 (sLDL 
TBARS and sLDL diene) after induction of oxidation.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The baseline blood samples showed no difference between 
the groups for LDL diene and TBARS levels. The atherogenic 
diet (Group 3 and Group 4) caused a pronounced increase in 
both basal and Cu2+-stimulated LDL-conjugated diene levels 
(P , 0.01, Figure 1A). bLDL TBARS levels after 7 weeks 
of the atherogenic diet showed no significant difference, but 
Cu2+-stimulated sLDL TBARS levels at 110 minutes for both 
atherogenic diet groups were significantly higher than for the 
normal diet groups (P , 0.01, Figure 1B).
Eight weeks of treatment with atorvastatin significantly 
decreased both sLDL TBARS levels (25.3%, P , 0.05) and 
sLDL-conjugated diene levels (25.5%, P , 0.01) in Group 
4 in comparison with the atherogenic diet group not receiv-
ing atorvastatin treatment (Group 3). There was a signifi-
cant difference between the results for the atherogenic diet 
groups with and without atorvastatin treatment (Group 3 and 
Group 4, respectively) for LDL TBARS (P , 0.01) and LDL-
  conjugated diene levels (P , 0.05, Figures 1A and 1B).
Table 1 Serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels throughout the experiment
Median/percentile  
(10%–90%)
Group 1  
Normal diet  
(n = 11)
Group 2  
Normal diet +  
atorvastatin (n = 10)
Group 3  
Hypercholesterolemic  
diet (n = 9)
Group 4  
Hypercholesterolemic  
diet + atorvastatin (n = 10)
TC (mg/dL)
0 110 (91–137) 116 (90–141) 116 (72–144) 113 (89–149)
Week 7 114 (87–141) 117 (78–133) 1841a,b,x (1111–2599) 1687a,b,x (1112–2142)
Week 15 111 (89–137) 92 (67–105) 2015a,b,x (1097–2913) 1135a,b,c,x,y (975–1365)
LDL (mg/dL)
0 70 (51–102) 77 (36–86) 72 (25–100) 56 (43–97)
Week 7 78 (58–99) 73 (36–97) 1658a,b,x (1002–2420) 1517a,b,x (955–1936)
Week 15 63 (46–95) 49φ,y (21–82) 1807a,b,x (857–2658) 1130a,b,ε,x,γ (739–1507)
HDL (mg/dL)
0 19 (14–31) 27 (15–31) 21 (14–27) 25 (14–33)
Week 7 18 (11–37) 21 (12–30) 121a,b,x (28–212) 121a,b,x (113–188)
Week 15 20 (13–35) 20x (11–25) 132a,b,x (82–217) 104a,b,x,y (91–181)
Triglycerides (mg/dL)
0 105 (20–171) 98 (47–228) 104 (94–166) 109 (97–159)
Week 7 112 (64–194) 116 (49–222) 261a,b,x (113–482) 357a,b,x (193–432)
Week 15 124 (71–282) 67 (46–285) 287a,b,x (191–450) 362a,b (241–706)
Notes: aP , 0.01, Mann–Whitney U test, vs group 1 (controls); bP , 0.01, Mann–Whitney U test vs group 2; cP , 0.01, εP , 0,05; Mann–Whitney U test, comparison 
between group 3 and group 4 are evaluated; xP , 0.01; φP , 0.05, Wilcoxon signed-rank test, vs first blood samples within the same group; yP , 0.01; γP , 0.05, Wilcoxon 
signed-rank test vs week 7 and week 15 blood samples.
Abbreviations: LDL, low-density cholesterol; HDL, high-density cholesterol; Tc, total cholesterol.
Table 2 erythrocyte, superoxide dismutase, and catalase activity, and TBARS levels
Median/percentiles  
(10%–90%)
Group 1 
Normal diet  
(n = 11)
Group 2  
Normal diet +  
atorvastatin (n = 10)
Group 3  
Hypercholesterolemic  
diet (n = 9)
Group 4  
Hypercholesterolemic  
diet + atorvastatin (n = 10)
eSOD (U/gHb)
Start 3333 (1965–5039) 3064 (1537–4610) 2835 (1727–5423) 2984 (1274–6393)
Week 7 3196 (2734–4461) 2997 (2053–4198) 6973a,b,d (5478–8392) 7237a,b,x (4011–10,259)
Week 15 3655 (2919–4885) 3188 (1767–3950) 8101a,b,d (4706–13,084) 5620a,b,ε,x,γ (3964–9325)
eCAT (U/g Hb)
Start 9013 (8258–12,015) 9106 (6585–12,637) 9307 (7023–10,919) 9342 (8821–10,815)
Week 7 9335 (8478–10,821) 9603 (7690–12,872) 10043α,φ (8239–18,888) 12245α,φ (7202–20,126)
Week 15 9232 (8306–11,045) 9521 (8336–11,776) 10532α,φ (9227–17,192) 10531 (6523–14,025)
eTBARS (nmol/g Hb)
Start 4210 (2948–4811) 4365 (3444–4903) 3994 (3348–4973) 4537 (3180–5715)
Week 7 4110 (3338–5457) 4363 (4076–5174) 7463a,b,d (6515–9457) 8415a,b,x (4607–12,748)
Week 15 4283 (2915–5083) 4429 (4039–5147) 7035a,b,d (6054–14,518) 6688a,b,x,γ (4083–10,155)
Notes: aP , 0.01; αP , 0.05, Mann–Whitney U test vs group 1 (controls); bP , 0.01, Mann-Whitney U test, vs group 2; εP , 0.05, Mann–Whitney U test vs group 3 and 
group 4; dP , 0.01; φP , 0.05; Wilcoxon signed-rank test vs first blood samples, within the same group; γP , 0.05; Wilcoxon signed-rank test vs second and third blood 
samples.
Abbreviations: e, erythrocyte; Hb, hemoglobin; cAT, catalase; SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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As shown in Figure 2, paraoxonase activity in all groups 
showed no difference at baseline. In the second blood samples 
taken at week 7, paraoxonase activity in the atherogenic diet 
groups (Group 3 and Group 4) was significantly lower than 
in the normal diet groups (Group 1 and Group 2, P , 0.01). 
Evaluation within the same groups showed that the athero-
genic diet decreased paraoxonase activity significantly 
(P , 0.01). Atorvastatin treatment caused an increase in 
paraoxonase activity in Group 4 (P , 0.01), but this increase 
was not statistically significant in comparison with untreated 
hypercholesterolemic rabbits in Group 3.
Oxidant–antioxidant status in aortic tissue
Superoxide dismutase activity in the arcus aortic tissues from 
the atherogenic diet group was significantly higher than in 
the control group (P , 0.01, Figure 3). Superoxide dismutase 
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Figure 1 A) 0 minutes (basal) and 110 minutes (after induction of oxidation with cu2+) values of LDL-conjugated diene and B) LDL TBARS levels of all groups by the time 
of the experiment. 
Notes: ∗P , 0.01, Mann–Whitney U test vs group 1 (controls); οP , 0.01, Wilcoxon signed-rank test; comparison of values before and after atorvastatin treatment within 
the group.
Abbreviations: LDL, low-density lipoprotein; TBARS, thiobarbituric acid reactive substances.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
338
Sezer et al
activity in Group 4 was as low as in the control group. 
Superoxide dismutase and catalase activity in aortic tissue 
did not show any significant difference between the treatment 
groups. Malondialdehyde levels in the aortic tissues of the 
atherogenic diet group was significantly higher than in the 
control group (P , 0.01), and atorvastatin treatment lowered 
malondialdehyde levels to basal values (Figure 3).
Histopathological examination  
of arcus aortic tissue
Histological sections of arcus aortic tissue were stained with 
hematoxylin and eosin and examined microscopically. The 
microscopic images of the arcus aortic sections of the normal 
diet groups appeared normal, with organized intimal surfaces 
 ( Figure 4A). In the microscopic images obtained for arcus   aortic 
sections from the hypercholesterolemic group without any 
  treatment (Group 3), thick atherosclerotic plaques were observed 
surrounding the intima, and the arterial lumina were   visibly 
obstructed by these plaques. Leukocyte infiltrations were 
  noticeable in the intima of these specimens (Figures 4B and 4C). 
In Group 4, which received atorvastatin treatment, it was 
observed that plaque formation was totally or partially repressed, 
and significantly localized (Figures 4D, 4E, and 4F).
Discussion
Even though atherosclerosis is a complex, progressive, 
and multifactorial disease, nowadays there is no doubt that 
elevated plasma cholesterol levels play a dominant role in its 
pathogenesis. HMG-CoA reductase inhibitors, ie, statins, are 
widely prescribed in many countries to lower cholesterol levels 
in patients at risk.14 In this study, we investigated the effect of 
atorvastatin on the oxidant–antioxidant status of LDL choles-
terol and erythrocytes, as well as in arcus aortic tissue.
In the animal model used, an atherogenic diet severely 
increased cholesterol levels (Table 1). Plasma total choles-
terol and LDL cholesterol levels reached about 20 times the 
initial values, consistent with the results of another study 
reported by Bustos et al.15 The increase in triglyceride levels 
may have been associated with the addition of butter to the 
atherogenic diet.
Besides being a potent HMG-CoA reductase inhibitor, 
atorvastatin also has the longest half-life among the available 
statins, which contributes to its high efficacy. In view of this 
and conflicting reports about the antioxidant characteristics of 
the drug, atorvastatin was chosen from the available statins 
for this study. The dose of atorvastatin used (5 mg/kg/day) 
was decided on the basis of previous experiments using 1, 
2.5, and 10 mg/kg/day.15
It must be emphasized that, in contrast with other studies, 
we did not start atorvastatin treatment at the beginning of the 
experiment, but started it after 7 weeks of the atherogenic 
diet, in order to mimic conditions of human atherosclerosis, 
where statins are used in most cases after atherogenesis is 
established. Most studies in humans are performed after the 
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onset of clinical signs when the disease is well advanced. In 
this respect, animal models are more convenient to use 
because they allow study of the initiation and progression of 
the preclinical stages of atherosclerosis in a more controlled 
setting within a shorter period of time. As expected, ator-
vastatin achieved a 25% decrease in LDL cholesterol levels, 
consistent with previous studies.15–17
LDL levels in the atherogenic diet group were higher than 
in the control group in spite of treatment with atorvastatin, 
probably due to the excessive amount of cholesterol added 
to the diet. However, this gave us the opportunity to examine 
and compare the beneficial effects of atorvastatin additional 
to lowering of cholesterol levels.
Erythrocytes are a very appropriate medium via which cho-
lesterol can exert a pro-oxidant action due to the potential for 
free radical generation. Therefore, in this study, oxidant status 
was studied in erythrocytes18,19 as well as in LDL fractions. 
Our results show that an atherogenic diet caused a prominent 
increase in superoxide dismutase and catalase antioxidant 
activity and also in TBARS levels (Table 2). The increase in 
superoxide dismutase activity represents an important physi-
ological adaptation counteracting the increase in oxidative 
stress.19 The enhanced levels of TBARS are also an indicator 
of the oxidant stress induced by hypercholesterolemia. In this 
study, the increase in TBARS levels in spite of enhanced 
superoxide dismutase activity suggests that the elevation in 
superoxide dismutase activity was inadequate for complete 
prevention of lipid peroxidation in the hypercholesterolemic 
group. The significant decrease in superoxide dismutase 
activity in erythrocytes and changes in TBARS levels after 8 
weeks of atorvastatin treatment, indicate the antioxidant effect 
of the drug, in support of previous studies.20,21
Wassmann et al22 reported increased catalase protein 
expression and enzyme activity following upregulation of 
catalase mRNA, with no significant alteration in mRNA 
expression of superoxide dismutase in vascular smooth 
muscle cells in vitro. In the same study, while atorvastatin did 
not have any significant effect on vascular mRNA expression 
of superoxide dismutase, vascular catalase mRNA expres-
sion was increased in the aortic tissue of hypertensive rats 
treated with atorvastatin in comparison with controls. In 
the present study, the changes in superoxide dismutase and 
catalase activity coincide with the in vivo results of the study 
reported by Wassmann et al. The more distinctive changes in 
superoxide dismutase activity than in catalase activity may 
be due to the different animal models used.
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Figure 3 A) Superoxide dismutase activity, B) catalase activity, C) malondialdehyde levels in the arcus aorta tissue of different groups of subjects.
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Atorvastatin and its metabolites formed in in vivo cir-
cumstances may prevent enhancement of the hydroxyl and 
peroxyl radicals generated by hypercholesterolemia, probably 
via their radical scavenging, metal-chelating capacity, and 
the attenuating effect on output of superoxide anions.
In this study, LDL TBARS and LDL-conjugated diene 
levels were measured at baseline and after induction of oxida-
tion using Cu2+ to evaluate the oxidation status of LDL. The 
significant increase in LDL TBARS and LDL-conjugated 
diene levels in the hypercholesterolemic rabbits represents the 
effect of hypercholesterolemia on the oxidative modification 
of LDL, probably via increased susceptibility to oxidation.2
The results of this study demonstrate the success of ator-
vastatin therapy in alleviating the production of LDL TBARS 
and LDL-conjugated diene. The oxidatively modified lipids 
and their degradation products are believed to have proin-
flammatory, immunogenic, and cytotoxic properties which 
contribute to both the initiation and progression of athero-
sclerotic lesions. It is reported that products of oxidatively 
modified LDL contribute to recruitment of monocytes and 
T cells, directly or indirectly, via induction of chemokines 
and endothelial cell adhesion molecules.2 The present study 
supports this hypothesis, with histopathological examination 
showing atherosclerotic plaque formation and nearly 50% 
luminal narrowing (Figures 1A and 1B) in aortic tissue from 
the nontreated atherogenic diet group.
There is no doubt that statins have a positive effect on 
regulation of total cholesterol and LDL cholesterol levels. 
Some authors have suggested that inhibition of LDL oxida-
tion by statins may be independent of any lipid-lowering 
effects.23 According to earlier studies, statins were assumed 
to reduce susceptibility of LDL to in vitro oxidation.24 It has 
been suggested that the inhibitory effect of statins on LDL 
oxidation may result from enhanced removal from plasma of 
“aged” LDL, which is more prone to oxidation than newly 
synthesized LDL. This effect could be due to statin-induced 
stimulation of LDL receptor activity in liver cells and to the 
inhibition of very low-density LDL (VLDL) and LDL pro-
duction in the liver.25 However, a few studies have reported 
that, with the exception of fluvastatin, none of the parent 
forms of the hypolipidemic drugs studied demonstrated a 
direct inhibitory antioxidant effect on LDL oxidation.26
Singh et al reported that atorvastatin therapy had a dose-
response effect with regard to decreasing oxidized LDL. 
They also reported other pleiotropic effects of the drug, 
evidenced by a significant decrease in related inflamma-
tory markers, including high sensitivity C-reactive protein, 
matrix metalloproteinase-9, and NF-κB activity, especially 
at high doses, ie, 80 mg/day.27 Aviram et al reported that 
atorvastatin did not affect oxidation of LDL in vitro, even at 
high concentrations.20 However, low pharmacological con-
centrations of specific hydroxylated metabolites of the drug 
C
Group  – Hypercholesterolemic diet 
A
Group 1 – Normal diet 
B
Group 3 – Hypercholesterolemic diet 
D
Group 4 – Hypercholesterolemic diet + atorvastatin 
E
Group 4 – Hypercholesterolemic diet + atorvastatin  Group 4 – Hypercholesterolemic diet + atorvastatin 
F
Figure 4 Histological images of arcus aorta tissues of different groups. A) group 1, normal diet, normal epithelial and intimal lamina; B, C) group 3, hypercholesterolemic 
diet and with huge atherosclerotic plaques surrounding the lumen; D–F) group 4, hypercholesterolemic diet and atorvastatin treatment, with thin and limited atherosclerotic 
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demonstrated a very potent inhibitory effect on LDL, VLDL, 
and HDL oxidation, both in metal ion-dependent and metal 
ion-independent systems. The molecular structure of ator-
vastatin hydroxymetabolites enables them to act as electron 
donors and, hence, as potent antioxidants.20 Therefore, it 
may be proposed that even if the parent drug does not show 
antioxidant properties, its metabolites may have antioxidant 
activity in vivo. This may be the reason for the conflicting 
data generated by in vivo and ex vivo studies.
The scientific debate continues on how HDL exerts its 
protective effect against atherosclerosis. Until recently, 
the focus of attention was on the role of HDL in reverse 
cholesterol transport. The human serum paraoxonase 1 
enzyme might be one of the ways in which HDL exerts 
its antiatherogenic action.28,29 Serum paraoxonase 1 is a 
45 kDa glycoprotein which is tightly bound to HDL sub-
fractions containing apolipoprotein A-I and apolipoprotein 
J (clusterin).30 Paraoxonase 1 hydrolyzes aromatic carboxylic 
acid esters, organophosphates, carbamates, and lactones, 
and acts to protect LDL against oxidative modification, 
thereby exhibiting anti-atherogenic and anti-inflammatory 
effects.29 This proposal is based on the studies of Aviram 
and Mackness who showed that in vitro supplementation 
of human HDL or whole serum with purified paraoxonase 
1 significantly inhibited Cu2+-induced lipoprotein oxidation 
in a concentration-dependent manner.28,31,32 The results of 
the present study show that an atherogenic diet results in 
a sharp decrease in paraoxonase activity, leading to loss of 
another guardian against oxidation and atherosclerosis. The 
inadequate paraoxonase activity seen in the atherogenic diet 
groups in this study probably contributes to the increased 
levels of oxidation markers (TBARS, oxidized LDL, LDL-
conjugated dienes). The low paraoxonase activity observed 
in the atherogenic diet groups is consistent with the results 
of other research.32
Loss of antioxidant paraoxonase activity from HDL or 
repressed expression of the enzyme may explain the decrease 
in paraoxonase activity seen with an atherogenic diet. In this 
study, although paraoxonase activity was studied, paraoxo-
nase mass or expression was not assayed, so more detailed 
information will have to come from further studies.
Leitinger et al reported that an atherogenic diet resulted 
in the formation of oxidized phospholipids in livers of mice 
rendered genetically susceptible to diet-induced athero-
sclerosis.34 These oxidized phospholipids are believed to 
induce an acute-phase response which results in production 
of proinflammatory HDL susceptible to atherosclerosis.34 
LDL-derived oxidized phospholipids were found to induce 
interleukin-6 in hepatocytes and to repress paraoxonase 
mRNA levels. In humans, paraoxonase 1 activity and serum 
HDL susceptibility to oxidation are reported to be inversely 
related in several groups of patients with increased risk for 
atherosclerosis, such as those with hypercholesterolemia, 
noninsulin-dependent diabetes, or vascular disease.32,35,36
Superoxide dismutase and catalase activity and malondi-
aldehyde levels in aortic tissue gave us the chance to com-
pare and evaluate oxidant status in aortic tissues from 
different groups (Figure 3). The results obtained coincide 
with the findings for LDL fractions and erythrocytes. 
Superoxide dismutase activity in the aortic tissue from the 
atherogenic diet group was significantly higher than in Group 
1 controls. Superoxide dismutase activity in Group 4 rabbits 
receiving statin treatment with an atherogenic diet was as 
low as in Group 1 controls. Catalase activity in the same 
tissues did not show any statistically significant difference 
between groups, even though there was a slight increase of 
activity in the atherogenic diet group. These results can be 
explained as a collaborative interplay for defense against 
the rise of free oxygen radicals.18 Lipid peroxidation and 
aortic antioxidant defense mechanisms take action before 
the formation of gross lipid infiltration in the vessels of 
animals receiving an atherogenic diet, and some antioxidant 
mechanisms may act more prominently than others during 
this interplay.37 Other studies have also demonstrated signifi-
cantly increased enzymatic activity and protein expression 
of superoxide dismutase in macrophage-rich atherosclerotic 
lesions in accordance with our data.38,39 The vessel wall 
being 100-fold richer than the other tissues for extracellular 
superoxide dismutase activity may also be the reason why 
the changes in the superoxide dismutase activity both in 
hypercholesterolemia and atorvastatin treatment were more 
expressive than the catalase activity observed in the aortic 
tissue.40 Malondialdehyde levels showed a two-fold increase 
in the atherogenic diet group in comparison with controls, 
and atorvastatin therapy lowered the levels of malondial-
dehyde to a point even lower than the control group. The 
aortic tissue probably was the best medium for atorvastatin 
to show its antioxidant and antiatherosclerotic effects, which 
are clearly shown by the oxidant status markers and histo-
pathological data (Figure 4). The reason for this is probably 
because atherosclerosis is a complex and   miscellaneous 
disease, and atorvastatin not only has a favorable influence 
on oxidation and lipid profiles, but also exhibits pleiotropic 
effects on inflammation, macrophage accumulation, and 
even the calcification phases the atherosclerotic plaque goes 
through.27,41–44 Reflecting the summation of all these effects Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of atorvastatin, aortic tissue was the best medium through 
which to observe the outcome of treatment.
Even though animal studies are very valuable, some 
mechanisms may differ from those in humans, and this may 
be one of the limitations of this study. Another limitation 
was that the animals did not undergo angiography. However, 
the histological data obtained at the end of the experiment 
could not have been obtained in human patients, and that is 
an advantage of the present study and similar studies carried 
out using animal models.
Conclusion
The benefit of atorvastatin therapy certainly appears to exceed 
the cholesterol-lowering effects of the statins, and this study 
provides evidence that atorvastatin has an anti-atherogenic 
effect in a primary prevention setting, not just by decreasing 
lipid levels, but also by suppressing oxidation of LDL. The 
beneficial effect of atorvastatin on oxidative status seems to 
be one of its most important benefits, ie, a preventative effect 
on plaque formation.
Despite the discussion on the widespread use of statins 
and at what point their use is essential, the present study 
shows that atorvastatin has a dramatic anti-atherosclerotic 
effect, and part of this effect seems to be due to the anti-
oxidant features of the parent drug and/or its metabolites, 
favoring inhibition of LDL oxidation in addition to its other 
pleiotropic effects. We believe comprehending the entire 
spectrum of benefits associated with atorvastatin therapy 
would allow better therapeutic application and foster the 
early and appropriate use of a statin.
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